CytoTools AG

As of December 31, 2023, CytoTools AG has 577,470.00 shares outstanding.

These figures are as of December 31, 2023. The price-to-sales ratio is 14.80, and the price-to-book ratio stands at -0.01.

As of December 31, 2023, CytoTools AG maintains a current ratio of 7.18, meaning it holds 7.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2023. Return on assets (ROA) is negative at -187.95, reflecting losses generated across the asset base.

Over the twelve months ended December 31, 2023, CytoTools AG posted a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -4,861.98 and net profit margin of -120,369.08 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2023. Free cash flow yield is negative at -283.53: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.

CytoTools AG's most recent stock split took place on April 27, 2022 with a 100:103 split ratio.

As of December 31, 2023, CytoTools AG has an Altman Z-Score of -89.10, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.